GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Price-to-Free-Cash-Flow

Insulet (Insulet) Price-to-Free-Cash-Flow

: 362.52 (As of Today)
View and export this data going back to 2007. Start your Free Trial

As of today (2024-04-18), Insulet's share price is $168.57. Insulet's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.47. Hence, Insulet's Price-to-Free-Cash-Flow Ratio for today is 362.52.

The historical rank and industry rank for Insulet's Price-to-Free-Cash-Flow or its related term are showing as below:

PODD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 353.35   Med: 431.18   Max: 2698.57
Current: 362.42

During the past 13 years, Insulet's highest Price-to-Free-Cash-Flow Ratio was 2698.57. The lowest was 353.35. And the median was 431.18.

PODD's Price-to-Free-Cash-Flow is ranked worse than
96.73% of 336 companies
in the Medical Devices & Instruments industry
Industry Median: 31.405 vs PODD: 362.42

Insulet's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.16. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.47.

During the past 13 years, Insulet's highest 3-Year average Free Cash Flow per Share Growth Rate was 67.00% per year. The lowest was -137.90% per year. And the median was 22.10% per year.


Insulet Price-to-Free-Cash-Flow Historical Data

The historical data trend for Insulet's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 437.46

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 437.46

Competitive Comparison

For the Medical Devices subindustry, Insulet's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Insulet's Price-to-Free-Cash-Flow falls into.



Insulet Price-to-Free-Cash-Flow Calculation

Insulet's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=168.57/0.465
=362.52

Insulet's Share Price of today is $168.57.
Insulet's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Insulet  (NAS:PODD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Insulet Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Insulet's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730